Mirum Pharmaceuticals Stock Investor Sentiment
| MIRM Stock | USD 45.25 1.19 2.70% |
About 51% of Mirum Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Mirum Pharmaceuticals suggests that many traders are impartial. Mirum Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Mirum Pharmaceuticals. Many technical investors use Mirum Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Mirum |
Mirum Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Mirum Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Mirum Pharmaceuticals that are available to investors today. That information is available publicly through Mirum media outlets and privately through word of mouth or via Mirum internal channels. However, regardless of the origin, that massive amount of Mirum data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Mirum Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Mirum Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Mirum Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Mirum Pharmaceuticals alpha.
Mirum Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Longpre Lara of 434 shares of Mirum Pharmaceuticals at 22.287 subject to Rule 16b-3 | 12/19/2024 |
2 | Disposition of 750 shares by Howe Jolanda of Mirum Pharmaceuticals at 42.8153 subject to Rule 16b-3 | 01/07/2025 |
3 | Disposition of 1379 shares by Pamela Vig of Mirum Pharmaceuticals at 20.6223 subject to Rule 16b-3 | 01/08/2025 |
4 | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 01/10/2025 |
5 | Disposition of 6969 shares by Quan Joanne of Mirum Pharmaceuticals at 45.86 subject to Rule 16b-3 | 01/17/2025 |
6 | Acquisition by Christopher Peetz of 38390 shares of Mirum Pharmaceuticals subject to Rule 16b-3 | 01/21/2025 |
7 | Disposition of 12500 shares by Christopher Peetz of Mirum Pharmaceuticals subject to Rule 16b-3 | 01/23/2025 |
8 | Disposition of 6837 shares by Christopher Peetz of Mirum Pharmaceuticals at 47.9243 subject to Rule 16b-3 | 01/24/2025 |
9 | Disposition of 1772 shares by Jolanda Howe of Mirum Pharmaceuticals subject to Rule 16b-3 | 01/31/2025 |
10 | Disposition of 1064 shares by Jolanda Howe of Mirum Pharmaceuticals at 48.2225 subject to Rule 16b-3 | 02/03/2025 |
11 | Disposition of 9102 shares by Christopher Peetz of Mirum Pharmaceuticals at 48.2225 subject to Rule 16b-3 | 02/04/2025 |
12 | Acquisition by Longpre Lara of 965 shares of Mirum Pharmaceuticals at 10.64 subject to Rule 16b-3 | 02/26/2025 |
13 | Mirum Pharmaceuticals Inc Q4 2024 Earnings Call Highlights Record Sales Surge and ... | 02/27/2025 |
14 | Mirum Pharmaceuticals Full Year 2024 Earnings EPS Misses Expectations | 02/28/2025 |
15 | Disposition of 20608 shares by Christopher Peetz of Mirum Pharmaceuticals at 47.19 subject to Rule 16b-3 | 03/03/2025 |
16 | Disposition of 1169 shares by Radovich Peter of Mirum Pharmaceuticals at 45.74 subject to Rule 16b-3 | 03/04/2025 |
17 | Cantor Fitzgerald Has Positive View of MIRM FY2025 Earnings | 03/05/2025 |
Check out Mirum Pharmaceuticals Hype Analysis, Mirum Pharmaceuticals Correlation and Mirum Pharmaceuticals Performance. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share | Quarterly Revenue Growth 0.429 | Return On Assets | Return On Equity |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.